Puma Biotechnology Inc (PBYI) carries a Roarable Rating of C+ (Hold) with 67/100 RQD Confidence. The composite score sits in the neutral Hold band (59–69), meaning current holders don’t need to panic-sell while prospective buyers can wait for a move into the 70+ Buy zone.
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
FRED Regime × Technicals: 86% of 52W Range • RSI-14 at 52.9 (NEUTRAL RANGE)
SEC Form 4 / 13F Thermometer: 85% Net Buy • Cannibal Buyback (-2.64% YoY Shares)
Balance-sheet & 10-K footnote risk deducts 11 pts from forensic ceiling
Even with a 67/100 (C+) score, PBYI faces multiple-compression risk if 17.5x trailing P/E re-rate toward historical sector medians or if hyperscaler/enterprise customer concentration slows in upcoming 10-Q filings.
Recent SEC filings added new risk-factor disclosures that warrant keeping an eye on margins.
Dilution & Margin Drag: Cannibal Buyback (-2.64% YoY Shares) — any gross margin slip below 72.0% triggers an automatic RQD downgrade.
Technical & Forensic Kill-Switch: A daily close below the 50D SMA ($9.82) or 200D SMA ($7.91) invalidates the momentum regime and cuts Target Base ($10.97) toward Bear Floor ($8.56).
Puma Biotechnology Inc (PBYI) slipped -0.75% to $10.54, trading at 86% of its 52-week range ($4.58 – $11.5). Solid 75% profit margin (29% return on capital), mixed timing at 18x P/E—hold if owned, no rush to chase.
LOS ANGELES, October 22, 2026--Puma Biotechnology will issue its third quarter 2026 results and host a conference call on Thursday, November 5, 2026, after the close.
PBYI raised its 2026 Nerlynx sales outlook after 3.5% first-half 2026 growth, with Q3 revenues expected to reach $54-$56 million.
AstraZeneca, Roche, Puma Biotechnology and Olema Oncology offer breast cancer treatment opportunities, with drug sales growth, pipeline advances and clinical milestones shaping prospects.
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
vs. -0.9% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
No active Ellis Vennor swing setup published on PBYI today. View full Setup Ledger →
No direct multi-tier Butterfly edges indexed yet for PBYI. Explore sector supply chains on /butterfly.
Across 1016 tracked Health Care securities in the Roarable RQD universe, Puma Biotechnology Inc (PBYI) ranks #121 by composite RQD confidence (67/100, grade C+) and #432 by equity capitalization ($544.1M). Within this direct 5-issuer industry benchmark cohort, PBYI leads on earnings valuation at 17.5x trailing P/E, while PBYI leads on capital efficiency and profitability with 29.3% ROIC and 74.5% gross margin. PBYI currently leads its immediate peer cohort in composite quantitative strength at 67/100 (C+).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| PBYI
ACTIVE
Puma Biotechnology Inc | C+ | 67/100 | 17.5x | 74.5% | 29.3% | -0.75% | $544.1M | Benchmark Subject |
| DRUG Bright Minds Biosciences Inc. | C- | 61/100 | — | — | — | +2.48% | $556.7M | /drug-vs-pbyi → |
| EVO Evotec SE | D+ | 57/100 | — | — | — | -1.56% | $562.1M | /evo-vs-pbyi → |
| CBIO Crescent Biopharma Inc. | D | 44/100 | — | — | -35.0% | +4.22% | $522.6M | /cbio-vs-pbyi → |
| ARVN Arvinas Inc. | D- | 37/100 | — | — | -32.1% | +3.95% | $516.6M | /arvn-vs-pbyi → |
In its most recent audited fiscal period (FY2025, filed 2025-12-31), Puma Biotechnology Inc (PBYI) reported GAAP revenue of $228.4M (-0.9% vs. FY2024 revenue of $230.5M , and -3.1% cumulative change since FY2023) , GAAP net income of $31.1M, operating cash flow of $41.8M, and free cash flow of $41.7M (+7.4% YoY). On the balance sheet, PBYI closed FY2025 with $216.3M in total assets against $0 in total debt (Altman Z-Score: 0.20, Piotroski F-Score: 8/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $228.4M | $31.1M | $41.8M | $41.7M | $216.3M | $0 |
| FY2024 (FY) | 2024-12-31 | $230.5M | $30.3M | $38.9M | $38.9M | $213.3M | $21.7M |
| FY2023 (FY) | 2023-12-31 | $235.6M | $21.6M | $27.0M | $27.0M | — | — |
As of 2026-11-01, Puma Biotechnology Inc (NASDAQ: PBYI) is rated C+ (Hold / HOLD) by Roarable's 5-pillar RQD engine with a composite confidence score of 67/100 at a spot price of $10.54 (-0.75% 1D, market cap $544.1M). Pillar breakdown: Fundamental Cash Engine 14/20, Institutional 13F & Options Flow 9/20, Executive Insider Alignment 9/20, FRED Macro Regime Fit 18/20, and SEC Balance-Sheet Forensics 17/20. Across 1016 tracked Health Care issuers, PBYI ranks #121 in composite RQD confidence.
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), PBYI carries a Roarable C+ (67/100 RQD), trailing P/E of 17.5x, gross margin of 74.5%, and ROIC of 29.3%. By comparison, DRUG (Bright Minds Biosciences Inc.) holds a C- grade (61/100 RQD, P/E N/A, ROIC —, cap $556.7M) and EVO (Evotec SE) posts a D+ grade (57/100 RQD, P/E N/A, ROIC —, cap $562.1M). Among the 5-stock peer group, PBYI leads on earnings multiple (17.5x) while PBYI leads on capital efficiency (29.3% ROIC).
Per PBYI's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001401667), Puma Biotechnology Inc generated $228.4M in revenue (-0.9% YoY), $31.1M in net income, and $41.7M in free cash flow against $216.3M in total assets and $0 in total debt. Key quantitative strengths: Company leadership has skin in the game with net positive insider conviction.. Primary risk factors monitored: Recent SEC filings added new risk-factor disclosures that warrant keeping an eye on margins.. Institutional options positioning shows a 50% call / 50% put premium split.
PBYI last traded at $10.54 (-0.75% on volume of 224,300 shares), positioning the stock +7.33% above its 50-day simple moving average ($9.82) and +33.25% above its 200-day simple moving average ($7.91). Across its 52-week range of $4.58 to $11.50, PBYI sits at the 86.1% percentile with a 14-day RSI of 52.9 (NEUTRAL RANGE) and an implied next-earnings move of ±9.6% ($9.53 to $11.55).
Why PBYI Stock slipped -0.75% Today — RQD Quant Desk Flash. Solid 75% profit margin (29% return on capital), mixed timing at 18x P/E—hold if owned, no rush to chase.